OCMI
BMY.RT

Oaktop Capital Management II’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Oaktop Capital Management II’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-704,991
Closed -$487K – 19
2020
Q4 		$487K Hold
704,991
– – 0.09% 19
2020
Q3 		$1.59M Buy
704,991
+350,000
+99% +$1,000K 0.35% 18
2020
Q2 		$1.27M Hold
354,991
– – 0.3% 18
2020
Q1 		$1.35M Hold
354,991
– – 0.41% 17
2019
Q4 		$1.07M Buy
+354,991
New +$923K 0.28% 16

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Oaktop Capital Management II's BMY.RT Position: Q1 2021 in Review

Oaktop Capital Management II sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 704,991 shares — an estimated $487K sold.

Oaktop Capital Management II first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $1.59M in Q3 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Oaktop Capital Management II reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Oaktop Capital Management II sold 704,991 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $487K.
  • Oaktop Capital Management II first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Oaktop Capital Management II's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $1.59M in Q3 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Oaktop Capital Management II's 13F filing for Q1 2021, filed 17 May 2021.